Angiotensin-Converting Enzyme Inhibitors Versus Angiotensin Receptor Blockers

Levy BI How to explain the differences between renin angiotensin system modulators . Am J Hypertens 2005;18(9 Pt 2): 134S-141S.

Santos RA , Ferreira AJ , Pinheiro SV , Sampaio WO , Touyz R. , Campagnole-Santos MJ Angiotensin-(1-7) and its receptor as a potential target for new cardiovascular drugs. Expert Opin Investig Drugs 2005;14:1019-31.

Pagliaro P. , Penna C. Rethinking the renin-angiotensin system and its role in cardiovascular regulation . Cardiovasc Drugs Ther 2005;19:77-87.

Doggrell SA Angiotensin AT-1 receptor antagonism: complementary or alternative to ACE inhibition in cardiovascular and renal disease? Expert Opin Pharmacother 2002;3:1543-56.

Reid JL Molecular-specific effects of angiotensin II antagonists: clinical relevance to treating hypertension? JRAAS 2005;6:15-24.

Henrion D. , Kubis N. , Levy BI Physiological and pathophysiological functions of the AT(2) subtype receptor of angiotensin II: from large arteries to the microcirculation. Hypertension 2001;38:1150-7.

Chai SY , Fernando R. , Peck G. , Ye SY , Mendelsohn FA , Jenkins TA , Albiston AL The angiotensin IV/AT4 receptor. Cell Mol Life Sci 2004;61:2728-37.

Carey RM Cardiovascular and renal regulation by the angiotensin type 2 receptor: the AT2 receptor comes of age. Hypertension 2005 ;45:840-44.

Ferrario CM , Trask AJ , Jessup JA Advances in biochemical and functional roles of angiotensin-converting enzyme 2 and angiotensin-(1-7) in regulation of cardiovascular function. Am J Physiol Heart Circ Physiol 2005;289:H2281-2290.

Pagliaro P. , Penna C. Rethinking the renin-angiotensin system and its role in cardiovascular regulation. Cardiovasc Drugs Ther 2005;19:77-87.

Li W. , Moore MJ , Vasilieva N. , Sui J. , Wong SK , Berne MA , Somasundaran M. , Sullivan JL , Luzuriaga K. , Greenough TC , Choe H. , Farzan M. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus . Nature 2003; 426:450-54.

Campbell DJ , Krum H. , Esler MD Losartan increases bradykinin levels in hypertensive humans. Circulation. 2005;111:315-20.

Fleming I. , Kohlstedt K. , Busse R. New fACEs to the renin-angiotensin system. Physiology (Bethesda) 2005;20:91-5.

Schupp M. , Clemenz M. , Gineste R. et al. Molecular Characterization of New Selective Peroxisome Proliferator-Activated Receptor {gamma} Modulators with Angiotensin Receptor Blocking Activity. Diabetes 2005; 54:3442-52.

Wilms H. , Rosenstiel P. , Unger T. , Deuschl G. , Lucius R. Neuroprotection with angiotensin receptor antagonists: a review of the evidence and potential mechanisms. Am J Cardiovasc Drugs 2005;5:245-53.

Campbell DJ , Zeitz CJ , Esler MD , Horowitz JD Evidence against a major role for angiotensin converting enzymerelated carboxypeptidase (ACE2) in angiotensin peptide metabolism in the human coronary circulation. J Hypertens 2004;22:1971-6.

Fox KM ; European trial on reduction of cardiac events with perindopril in stable coronary Artery Disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003;362:782-78.

Du X. , McNamee R. , Cruickshank K. Stroke risk from multiple risk factors combined with hypertension: a primary care based case-control study in a defined population of northwest England . Annals of Epidemiology 2000;10:380-8.

Wachtell K. , Lehto M. , Gerdts E. et al. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol 2005;45:712-19.

Pfeffer M. , McMurray JJV , Velazquez EJ et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003;349:1893-906.

Verma S. , Strauss M. , Angiotensin receptor blockers and myocardial infarction. BMJ 2004;329:1248-9.

Pfeffer MA , Swedberg K. , Granger CB et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003;362(9386):759-66.

Collins R. , MacMahon S. Blood pressure, antihypertensive drug treatment and the risks of stroke and of coronary heart disease. Br Med Bull 1994 ;50:272-98.

Blood Pressure Lowering Treatment Trialist Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003;62:1527-35.

Dahlöf B. , Devereux RB , Kjeldson SE et al, for the LIFE study group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol . Lancet 2002;359:995-1003.

Julius S. , KjeldsenSE, WeberM etal, forthe VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine the VALUE randomised trial. Lancet 2004;363:2022-31.

PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen study among 6105 individuals with previous stroke or transient ischaemic attack . Lancet 2001;3581:1033-41.

Schrader J. , Lüders S. , Kulschewski A. et al. Morbidity and mortality after stroke, eprosartan compared with nitrendipine for secondary prevention. Principal results of a prospective randomised controlled study (MOSES). Stroke 2005;36:1218-26.

Schrader J. , Lüders S. , Kulschewski A. et al; Acute Candesartan Cilexetil Therapy in Stroke Survivors Study Group. The ACCESS study: evaluation of Acute Candesartan Cilexetil Therapy in Stroke Survivors. Stroke 2003; 34:1699-703.